Category: ER+ Breast Cancer

Telaglenastat is a Selective and Orally Active Inhibitor of Glutaminase 1

Tumor cells use a variety of oncogenically- and environmentally driven metabolic pathways. That aims to meet the bioenergetic and biosynthetic demands of rapid and sustained growth. One of the key nutrients is the amino acid glutamine. It is the most abundant amino acid in plasma. Small-molecule inhibitors, suppressing the...

ERD-308, a PROTAC Degrader of ER, Has Potential to Treat ER+ Breast Cancer Treatment

In previous blogs, I have introduced some compounds based on PROTAC technology, including SJFδ, MS4077, BSJ-03-123, A1874, HJB97, Olutasidenib. Today, I’d like to introduce another novel compound ERD-308 as a highly potent PROTAC degrader of estrogen receptor (ER). Breast cancer (BC) is such a common malignancy in women worldwide....